Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967334 | 0.93 | HCRTR1 (0.51) | HCRTR1HCRTR2NPC1ALDH1A1 | |
| SCHEMBL1970881 | 0.92 | HCRTR1 (0.45) | HCRTR1HCRTR2NPC1ALDH1A1OXTR | |
| SCHEMBL1971125 | 0.90 | HCRTR1 (0.44) | HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL1969095 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2NPC1DRD2DRD3 | |
| SCHEMBL1965725 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2NPC1DRD2DRD3 | |
| SCHEMBL1966616 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2NPC1OXTRAVPR1A | |
| SCHEMBL1968475 | 0.88 | HCRTR1 (0.45) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1969080 | 0.88 | HCRTR1 (0.45) | HCRTR1HCRTR2NPC1DRD2DRD3 | |
| SCHEMBL1972064 | 0.88 | HCRTR1 (0.45) | HCRTR1HCRTR2NPC1DRD2DRD3 | |
| SCHEMBL1968757 | 0.88 | HCRTR1 (0.44) | HCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885NPC1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.